This Drug Could Prevent PAH in People with Scleroderma
source: shutterstock.com

This Drug Could Prevent PAH in People with Scleroderma

According to a story from Scleroderma News, findings from the recent Phase 2 EDITA clinical trial suggested that ambrisentan (marketed as Letairis), which is approved to treat pulmonary arterial hypertension…

Continue Reading This Drug Could Prevent PAH in People with Scleroderma
Higher PLR and PHR Linked to Worse Systemic Sclerosis Activity
A case of systemic sclerosis. Source: Nevit Dilmen / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

Higher PLR and PHR Linked to Worse Systemic Sclerosis Activity

  Although the medical field has made significant strides over the years, there is still a lot we don’t know about the body. For example, what can we learn about…

Continue Reading Higher PLR and PHR Linked to Worse Systemic Sclerosis Activity
Belimumab Granted Orphan Drug Designation for Systemic Sclerosis
A case of systemic sclerosis. Source: Nevit Dilmen / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

Belimumab Granted Orphan Drug Designation for Systemic Sclerosis

Initially, belimumab (sold under the brand name BENLYSTA) was approved for the treatment of patients for lupus and lupus nephritis. It was the first FDA-approved biologic treatment within this indication.…

Continue Reading Belimumab Granted Orphan Drug Designation for Systemic Sclerosis

Positive Phase 1 Trial Results for Systemic Sclerosis-Associated Interstitial Lung Disease Treatment

Prometheus Biosciences Inc. has just announced positive results from their Phase 1 investigation for a new treatment for systemic sclerosis-associated interstitial lung disease (SSC-ILD). This trial investigated PRA023, an anti-TL1A…

Continue Reading Positive Phase 1 Trial Results for Systemic Sclerosis-Associated Interstitial Lung Disease Treatment
June is Scleroderma Awareness Month: Spreading Rare Disease Awareness
source: pixabay.com

June is Scleroderma Awareness Month: Spreading Rare Disease Awareness

According to a story from Scleroderma News, June is recognized as Scleroderma Awareness Month. While physical distancing as a result of the ongoing coronavirus/COVID-19 pandemic may keep some folks at…

Continue Reading June is Scleroderma Awareness Month: Spreading Rare Disease Awareness
The Importance of Cancer Screenings in Patients with Scleroderma, Dermatomyositis
Elizabeth M. Dugan, Adam M. Huber, Frederick W. Miller, Lisa G. Rider / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

The Importance of Cancer Screenings in Patients with Scleroderma, Dermatomyositis

  This year, because of COVID-19, many healthcare-related events and symposiums have been moved online. However, that doesn't mean that the insights are any less helpful! In the virtual ACR…

Continue Reading The Importance of Cancer Screenings in Patients with Scleroderma, Dermatomyositis
Scleroderma Symptoms Shown to Be Alleviated with Tracleer Treatment
source: pixabay.com

Scleroderma Symptoms Shown to Be Alleviated with Tracleer Treatment

by Danielle Bradshaw from In The Cloud Copy A year-long study has shown that Tracleer greatly reduces the skin-related symptoms of scleroderma. The results also showed that although it helped…

Continue Reading Scleroderma Symptoms Shown to Be Alleviated with Tracleer Treatment
Phase 1 Study of Experimental Systemic Sclerosis Treatment Bermekimab Begins
PhotoLizM / Pixabay

Phase 1 Study of Experimental Systemic Sclerosis Treatment Bermekimab Begins

According to a recent press release from XBiotech, a Texas-based biotechnology company, patient dosing is now underway in a phase 1 clinical study of the Company's investigational systemic sclerosis treatment, bermekimab.…

Continue Reading Phase 1 Study of Experimental Systemic Sclerosis Treatment Bermekimab Begins
Findings From a Mouse Study Could Have Major Implications for Scleroderma
jarleeknes / Pixabay

Findings From a Mouse Study Could Have Major Implications for Scleroderma

According to a story from Scleroderma News, the results of a recent mouse study could have significant implications for the future of scleroderma treatment. In the study, scientists used a…

Continue Reading Findings From a Mouse Study Could Have Major Implications for Scleroderma
First Human Trial Completed for Experimental Scleroderma and Multiple Sclerosis Drug
stevepb / Pixabay

First Human Trial Completed for Experimental Scleroderma and Multiple Sclerosis Drug

According to a story from Financial Buzz, the drug developer Emerald Health Pharmaceuticals, Inc., recently announced that the company had completed a phase 1 clinical trial for its experimental drug…

Continue Reading First Human Trial Completed for Experimental Scleroderma and Multiple Sclerosis Drug